Italy's Amplifon Q1 revenue inches up

Amplifon SpA

05/05/2026 16:59

Overview

Italy hearing solutions provider's fiscal Q1 revenue grew 0.8% yr/yr

Adjusted net profit for fiscal Q1 rose 6.7% yr/yr

Adjusted EBITDA margin reached a record 24.5%, up 60 bps

Outlook

Amplifon expects 2026 organic growth above 3% compared to 2025

Company sees 2026 adjusted EBITDA margin improving by about 100 bps

Result Drivers

ORGANIC GROWTH - Amplifon said Q1 revenue increase was mainly driven by 2.2% organic growth across all regions

EFFICIENCY PROGRAM - Fit4Growth program contributed to profitability, but clinic closures and divestitures reduced revenue by 2.4%

ACQUISITIONS - Acquisitions completed mainly in 2025 contributed positively to Q1 revenue growth by 1.0%

Company press release: ID:nBIA8Fzs7P

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 579.8 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Amplifon SpA is €10.50, about 10.1% above its May 4 closing price of €9.54

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 19 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)